QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
ImmunityBio, Inc.
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
NextCure, Inc.
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
SWOG Cancer Research Network
Yonsei University
Alliance for Clinical Trials in Oncology
AmpliMed Corporation
M.D. Anderson Cancer Center
GlaxoSmithKline
Arog Pharmaceuticals, Inc.
M.D. Anderson Cancer Center